Teva Pharmaceuticals Completes Shift to Regular Stock Trading on NYSE
Teva Pharmaceuticals has marked a significant milestone by transitioning from trading American Depositary Shares (ADS) to regular stock on the New York Stock Exchange (NYSE), coinciding with the tenth anniversary of its major crisis. This move, initiated on the first trading day of the Hebrew year 5787, signifies not just a technical change but also a crucial business and symbolic shift for the Israeli drugmaker.
Ten years ago, Teva faced a severe crisis that threatened its existence, leading to an over 80% drop in its stock value within two years. While the company has not yet reached its peak valuation of $70 billion or record sales of $21 billion, its future is now viewed with renewed optimism. The transition to regular stock trading on the NYSE is expected to attract a wider range of institutional investors who were previously restricted from trading Teva's ADS, and potentially allow inclusion in major stock indices like the Russell 1000.
Under CEO Richard Francis, Teva's stock has quadrupled in the last five years, rising from $10 to $38, with most of the growth occurring in the last three and a half years. The company now boasts a market value of approximately $45 billion, making it the most valuable Israeli company listed on the stock exchange, excluding Palo Alto Networks. Teva is increasingly focusing on biopharmaceuticals and innovative drug development, moving away from its historical reliance on generic drugs, a strategy that has led to improved operational efficiency, reduced debt, and a credit rating upgrade.
Francis's 'Pivot to Growth' strategy, initiated in 2023, aims to transform Teva from a generic drug company into a leading biopharmaceutical firm. This involves focusing on developing treatments for chronic diseases with unmet needs, such as Crohn's disease, ulcerative colitis, and vitiligo, with potential blockbuster drugs like Austedo and Ajovy leading the charge. While generic drugs still constitute about half of Teva's revenue, providing a stable base, the company is investing heavily in its innovative pipeline, which includes biosimilar versions of complex drugs and new molecular entities.
Despite the positive trajectory, analysts note that Teva's transformation is ongoing, with a significant portion of revenue still derived from generics. The company's future success will depend on securing FDA approvals for its new drugs and demonstrating sustained growth. Teva recently made its first acquisition in a decade, purchasing Amlexan for $700 million to bolster its portfolio with treatments for conditions like Tourette syndrome, signaling a proactive approach to expanding its innovative offerings.
